title: Improving anti-HCV therapy.
abstract: Hepatitis C virus (HCV) infects about 2% of the world population or approximately 123 million people. The disease causes a significant level of morbidity and mortality among those afflicted. The combination of interferon and ribavirin is effective in many patients. However, the right treatment doses and duration, among other attributes, have a large impact on the treatment outcome.
authors.affiliation: Université Paris Descartes; APHP, Hôpital Cochin, Hépatologie; INSERM U. 567, Institut Cochin; Paris, France. stanislas.pol@cch.aphp.fr
authors.forename: Stanislas
authors.initials: S
authors.lastname: Pol
authors.forename: Vincent O
authors.initials: VO
authors.lastname: Mallet
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D012254:Ribavirin